Form 4/A for LEXX Lexaria Bioscience Corp.
Accepted 2022-10-18 00:00:00 ET · period of report 2022-10-12 · accession 0001855763-22-000019 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MAI | 2022-10-18 | 2022-10-12+ | LEXX | BUNKA CHRISTOPHER | CEO, Dir | P - Purchase | $2.04 | +38.5K | 254.4K | +18% | +$78.4K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | common shares | 2022-10-12 | P | A | 21,900 | $1.99 | 237,812 | I Private Holding Company | — | — | |
| 2 | Common | common shares | 2022-10-13 | P | A | 16,600 | $2.10 | 254,412 | I Private Holding Company | — | — |